211 related articles for article (PubMed ID: 36164553)
1. Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer.
Gu F; Hu C; Cao W; Li C; Xia Q; Gao Y; Liu Y; Gao S
Int J Nanomedicine; 2022; 17():4401-4417. PubMed ID: 36164553
[TBL] [Abstract][Full Text] [Related]
2. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.
Feng X; Li F; Zhang L; Liu W; Wang X; Zhu R; Qiao ZA; Yu B; Yu X
Acta Biomater; 2022 Apr; 143():392-405. PubMed ID: 35259519
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
[TBL] [Abstract][Full Text] [Related]
4. Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
Camilio KA; Wang MY; Mauseth B; Waagene S; Kvalheim G; Rekdal Ø; Sveinbjørnsson B; Mælandsmo GM
Breast Cancer Res; 2019 Jan; 21(1):9. PubMed ID: 30670061
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer.
Hu C; Liu Y; Cao W; Li N; Gao S; Wang Z; Gu F
Int J Nanomedicine; 2024; 19():507-526. PubMed ID: 38260240
[TBL] [Abstract][Full Text] [Related]
6. Dual fluorescence imaging-guided programmed delivery of doxorubicin and CpG nanoparticles to modulate tumor microenvironment for effective chemo-immunotherapy.
Dong X; Yang A; Bai Y; Kong D; Lv F
Biomaterials; 2020 Feb; 230():119659. PubMed ID: 31831223
[TBL] [Abstract][Full Text] [Related]
7. A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer.
Yao D; Wang Y; Bian K; Zhang B; Wang D
Biomaterials; 2023 Jan; 292():121920. PubMed ID: 36442436
[TBL] [Abstract][Full Text] [Related]
8. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
10. IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.
Santana-Krímskaya SE; Franco-Molina MA; Zárate-Triviño DG; Prado-García H; Zapata-Benavides P; Torres-Del-Muro F; Rodríguez-Padilla C
Biomed Pharmacother; 2020 Jun; 126():110062. PubMed ID: 32172064
[TBL] [Abstract][Full Text] [Related]
11. Complete rejection of large established breast cancer by local immunochemotherapy with T cell activation against neoantigens.
Gao J; Yuan X; Yuan J; Li L
Cancer Immunol Immunother; 2021 Nov; 70(11):3291-3302. PubMed ID: 33852044
[TBL] [Abstract][Full Text] [Related]
12. Nano-baicalein facilitates chemotherapy in breast cancer by targeting tumor microenvironment.
Zheng F; Luo Y; Liu Y; Gao Y; Chen W; Wei K
Int J Pharm; 2023 Mar; 635():122778. PubMed ID: 36842519
[TBL] [Abstract][Full Text] [Related]
13. Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment.
Zheng D; Wan C; Yang H; Xu L; Dong Q; Du C; Du J; Li F
Int J Nanomedicine; 2020; 15():10007-10028. PubMed ID: 33376321
[TBL] [Abstract][Full Text] [Related]
14. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
15. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy.
Wei X; Liu L; Li X; Wang Y; Guo X; Zhao J; Zhou S
J Control Release; 2019 Nov; 313():42-53. PubMed ID: 31629039
[TBL] [Abstract][Full Text] [Related]
16. Peptide-modified bioresponsive chondroitin sulfate micelles for targeted doxorubicin delivery in triple-negative breast cancer.
Yu J; Wang L; Ling Y; Xiao X; Gong J; Jin H; Xu J; Chen P; Xie X; Zhang L
Colloids Surf B Biointerfaces; 2023 Jul; 227():113381. PubMed ID: 37257299
[TBL] [Abstract][Full Text] [Related]
17. Integration of photothermal therapy and synergistic chemotherapy by a porphyrin self-assembled micelle confers chemosensitivity in triple-negative breast cancer.
Su S; Ding Y; Li Y; Wu Y; Nie G
Biomaterials; 2016 Feb; 80():169-178. PubMed ID: 26708642
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulator-Mediated Suppressive Tumor Immune Microenvironment Remodeling Nanoplatform for Enhanced Immuno/Chemo/Photothermal Combination Therapy of Triple Negative Breast Cancer.
Wang A; Yang X; Li R; Shao L; Zhao W; Hu X; Fang K; Chai K; Shi S; Dong C
ACS Appl Mater Interfaces; 2023 Nov; 15(46):53318-53332. PubMed ID: 37943829
[TBL] [Abstract][Full Text] [Related]
19. Construction of pH-Sensitive Nanovaccines Encapsulating Tumor Cell Lysates and Immune Adjuvants for Breast Cancer Therapy.
Ding Y; Yang J; Wei H; Wang J; Huang S; Yang S; Guo Y; Li B; Shuai X
Small; 2023 Sep; 19(37):e2301420. PubMed ID: 37154213
[TBL] [Abstract][Full Text] [Related]
20. Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer.
Liu Y; Qiu N; Shen L; Liu Q; Zhang J; Cheng YY; Lee KH; Huang L
J Control Release; 2020 Jul; 323():431-441. PubMed ID: 32360890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
